These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26091546)

  • 1. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical Use of Pharmacotherapy for Obesity.
    Igel LI; Kumar RB; Saunders KH; Aronne LJ
    Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 6. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 7. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
    Konstantinidou SK; Argyrakopoulou G; Simati S; Stefanakis K; Kokkinos A; Analitis A; Mantzoros CS
    Diabetes Obes Metab; 2024 Aug; 26(8):3147-3154. PubMed ID: 38757729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for obesity: What you need to know.
    Bersoux S; Byun TH; Chaliki SS; Poole KG
    Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
    Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
    Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.